Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

NCT03591744 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Budgetary constraints

Conditions

Plasma Cell Leukemia

Interventions

DRUG: Bortezomib
BIOLOGICAL: Daratumumab
DRUG: Dexamethasone
DRUG: Lenalidomide
DRUG: Pegylated Liposomal Doxorubicin Hydrochloride

Sponsor

City of Hope Medical Center

Collaborators

[object Object]